Bologna-Molina R, Mikami T, Pereira-Prado V, Pires FR, Carlos-Bregni R, Mosqueda-Taylor A. Primordial odontogenic tumor: An immunohistochemical profile. Med Oral Patol Oral Cir Bucal. 2017 May 1;22 (3):e314-23.

 

 

doi:10.4317/medoral.21859

http://dx.doi.org/doi:10.4317/medoral.21859

 

 

1. Mosqueda-Taylor A. New findings and controversies in odontogenic tumors. Med Oral Patol Oral Cir Bucal. 2008;13:555-8.

 

2. Mosqueda-Taylor A, Pires FR, Aguirre-Urzar JM, Carlos-Bregni R, de la Piedra-Garza JM, Martnez-Conde R, et al. Primordial odontogenic tumour: clinicopathological analysis of six cases of a previously undescribed entity. Histopathology. 2014;65:606-12.
https://doi.org/10.1111/his.12451

 

3. Slater LJ, Eftimie LF, Herford AS. Primordial Odontogenic Tumor: Report of a Case. J Oral Maxillofac Surg. 2016;74:547-51.
https://doi.org/10.1016/j.joms.2015.08.019

 

4. Bologna-Molina R, Damin-Matsumura P, Molina-Frechero N. An easy cell counting method for immunohistochemistry that does not use an image analysis program. Histopathology. 2011;59:801-3.
https://doi.org/10.1111/j.1365-2559.2011.03954.x

 

5. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
https://doi.org/10.1016/0092-8674(82)90400-7

 

6. Pelissier A, Ouhayoun JP, Sawaf MH, Forest N. Evolution of cytokeratin expression in developing human tooth germ. J Biolog Buccale. 1990;18:99-108.

 

7. Heikinheimo K, Hormia M, Stenman G, Virtanen I, Happonen RP. Patterns of expression of intermediate filaments in ameloblastoma and human fetal tooth germ. J Oral Pathol Med. 1989;18:264-73.
https://doi.org/10.1111/j.1600-0714.1989.tb00395.x

 

8. Crivelini MM, de Arajo VC, de Sousa SOM, de Arajo NS. Cytokeratins in epithelia of odontogenic neoplasms. Oral Dis. 2003;9:1-6.
https://doi.org/10.1034/j.1601-0825.2003.00861.x

 

9. Kumamoto H, Yoshida M, Ooya K. Immunohistochemical detection of amelogenin and cytokeratin 19 in epithelial odontogenic tumors. Oral Dis. 2001;7:171-6.
https://doi.org/10.1034/j.1601-0825.2001.70306.x

 

10. Mori M, Yamada K, Kasai T, Yamada T, Shimokawa H, Sasaki S. Immunohistochemical expression of amelogenins in odontogenic epithelial tumours and cysts. Virchows Arch. 1991;418:319-25.
https://doi.org/10.1007/BF01600161

 

11. Zalzal SF, Smith CE, Nanci A. Ameloblastin and amelogenin share a common secretory pathway and are co-secreted during enamel formation. Matrix Biol. 2008;27:352-9.
https://doi.org/10.1016/j.matbio.2008.01.003

 

12. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, et al. Epithelial cell adhesion molecule (ep-cam) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol. 1997;139:1337-48.
https://doi.org/10.1083/jcb.139.5.1337

 

13. Ord-ez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol. 1998;29:166-9.
https://doi.org/10.1016/S0046-8177(98)90227-1

 

14. Wang A, Ramjeesingh R, Chen CH, Hurlbut D, Hammad N, Mulligan LM, et. al. Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma. Curr Oncol. 2016;23:171-8.
https://doi.org/10.3747/co.23.3028

 

15. Bologna-Molina R, Gonzlez-Gonzlez R, Mosqueda-Taylor A, Molina-Frechero N, Damin-Matsumura P, Dominguez-Malagn H. Expression of Syndecan-1 in Papillary Carcinoma of the Thyroid with Extracapsular Invasion . Arch Med Res. 2010;401:33-7.
https://doi.org/10.1016/j.arcmed.2009.11.004

 

16. Trautman MS, Kimelman J, Bernfield M. Developmental expression of syndecan, an integral membrane proteoglycan, correlates with cell differentiation. Develop. 1991;111:213-20.

 

17. Hayashi K, Hayashi M, Jalkanen M, Firestone JH, Trelstad RL, Bernfield M. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J Histochem Cytochem. 1987;35:1079-88.
https://doi.org/10.1177/35.10.2957423

 

18. Vainio S, Jalkanen M, Vaahtokari A, Sahlberg C, Mali M, Bernfield M, et al. Expression of syndecan gene is induced early, is transient, and correlates with changes in mesenchymal cell proliferation during tooth organogenesis. Dev Biol. 1991;147:322-33.
https://doi.org/10.1016/0012-1606(91)90290-J

 

19. Elenius K, Salmivirta M, Inki P, Mali M, Jalkanen M. Binding of human syndecan to extracellular matrix proteins. J Biol Chem. 1990;265:17837-43.

 

20. Kioussi C, Briata P, Baek SH, Rose DW, Hamblet NS, Herman T, et al. Identification of a Wnt/Dvl/beta-catenin PITX2 pathway mediating cell-type-specific proliferation during development. Cell. 2002;111:673-85.
https://doi.org/10.1016/S0092-8674(02)01084-X

 

21. Wang Y, Li L, Zheng Y, Yuan G, Yang G, He F, et al. BMP activity is required for tooth development from the lamina to bud stage. J Dent Res. 2012;91:690-5.
https://doi.org/10.1177/0022034512448660

 

22. Mucchielli ML, Mitsiadis TA, Raffo S, Brunet JF, Proust JP, Goridis C. Mouse Otlx2/RIEG expression in the odontogenic epithelium precedes tooth initiation and requires mesenchyme-derived signals for its maintenance. Dev Biol. 1997;189:275-84.
https://doi.org/10.1006/dbio.1997.8672

 

23. Gordon N, Newton RW. Glucose transporter type1 (GLUT-1) deficiency. Brain Dev. 2003;25:477-80.
https://doi.org/10.1016/S0387-7604(03)00058-5

 

24. Snchez-Romero C, Bologna-Molina R, Mosqueda-Taylor A, Almeida OP. Immunohistochemical Expression of GLUT-1 and HIF-1α in Tooth Germ, Ameloblastoma, and Ameloblastic Carcinoma. Int J Surg Pathol. 2016;24:410-8.
https://doi.org/10.1177/1066896916640359

 

25. Martnez-Mata G, Mosqueda-Taylor A, Carlos-Bregni R, de Almeida OP, Contreras-Vidaurre E, Vargas PA, et al. Odontogenic myxoma: clinico-pathological, immunohistochemical and ultrastructural findings of a multicentric series. Oral Oncol. 2008;44:601-7.
https://doi.org/10.1016/j.oraloncology.2007.08.009

 

26. Newlaczyl AU, Yu LG. Galectin-3–a jack-of-all-trades in cancer. Cancer Lett. 2011;313:123-8.
https://doi.org/10.1016/j.canlet.2011.09.003

 

27. Tuğe C. Immunhistochemical expression of galectin-3 in cancer: a review of the literature. Trk Patoloji Dergisi. 2012:28:1-10.
https://doi.org/10.5146/tjpath.2012.01090

 

28. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Met Rev. 2007;26:605-10.
https://doi.org/10.1007/s10555-007-9095-6

 

29. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5:1087-98.
https://doi.org/10.1158/1535-7163.MCT-05-0375

 

30. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941-53.
https://doi.org/10.1200/JCO.1999.17.9.2941

 

31. Bast BT, Pogrel MA, Regezi JA. The expression of apoptotic proteins and matrix metalloproteinases in odontogenic myxomas. J Oral Maxillofac Surg. 2003;61:1463-6.
https://doi.org/10.1016/j.joms.2003.06.002

 

32. Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M. Immunohistochemical study on survivin in sinonasal tumors and its relationship with the immunoexpression of Ki67 and Bcl-2. Folia Histochem Cytobiol. 2013;51:225-31.
https://doi.org/10.5603/FHC.2013.0032

 

33. Basu A, Haldar S. The relationship between Bcl-2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod. 1998;4:1099-109.
https://doi.org/10.1093/molehr/4.12.1099

 

34. Del Carmen Gonzlez-Galvn M, Aguirre-Urizar JM, Bologna-Molina R, Farfn-Morales JE, Gainza-Cirauqui ML, Marichalar-Mendia X, et al. Assessment of CD-105 as an Angiogenic Modulator in Odontogenic Myxomas and Dental Follicles. Int J Surg Pathol. 2016;24:315-9.
https://doi.org/10.1177/1066896916632588

 

35. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood. 1990;75:2417-26.

 

36. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32:1380-9.
https://doi.org/10.1002/stem.1661

 

37. Brown J, Greaves MF, Molgaard HV. The gene encoding the stem cell antigen, CD34, is conserved in mouse and expressed in haemopoietic progenitor cell lines, brain, and embryonic fibroblasts. Int Immunol. 1991;3:175-84.
https://doi.org/10.1093/intimm/3.2.175

 

38. Nielsen JS, McNagny KM. Novel functions of the CD34 family. J Cell Sci. 2008;121:3683-92.
https://doi.org/10.1242/jcs.037507

 

39. Lin CS, Ning H, Lin G. Is CD34 truly a negative marker for mesenchymal stromal cells? Cytotherapy. 2012;14:1159-63.
https://doi.org/10.3109/14653249.2012.729817

 

40. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J. 2006;20:1045-54.
https://doi.org/10.1096/fj.05-5460rev

 

41. Silva FP, Dias A, Coelho CA, Guerra EN, Marques AE, Decurcio DA, et. al. Expression of CD90 and P75NTR stem cell markers in ameloblastomas: a possible role in their biological behavior. Braz Oral Res. 2016;30:109.
https://doi.org/10.1590/1807-3107BOR-2016.vol30.0109

 

42. Schwab W, Harada H, Goetz W, Nowicki M, Witt M, Kasper M, et al. Immunocytochemical and biochemical detection of EMMPRIN in the rat tooth germ: Differentiation-dependent co-expression with MMPs and co-localization with caveolin-1 in membrane rafts of dental epithelial cells. Histochem Cell Biol. 2007;128:195-203.
https://doi.org/10.1007/s00418-007-0313-7

 

43. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer and metastasis. Am J Phisiol. 2005;288:494-506.
https://doi.org/10.1152/ajpcell.00458.2004

 

44. Yang SF, Yang JY, Huang CH, Wang SN, Lu CP, Tsai CJ, et al. Increased caveolin-1 expression associated with prolonged overall survival rate in hepatocellular carcinoma. Pathol. 2010;42:438-45.
https://doi.org/10.3109/00313025.2010.494293

 

45. Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, et al. Loss of TGF- signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012;31:3322-32.
https://doi.org/10.1038/onc.2011.494

 

46. Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA. Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet. 2014;46:722-5.
https://doi.org/10.1038/ng.2986

 

47. Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, et al. Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res. 2014;20:5517-26.
https://doi.org/10.1158/1078-0432.CCR-14-1069

 

48. Diniz MG, Gomes CC, Guimares BV, Castro WH, Lacerda JC, Cardoso SV, et al. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumour Biol. 2015;36:5649-53.
https://doi.org/10.1007/s13277-015-3238-0